Randomized trial · people

Thymosin beta-4: no overall infarct area cut in 96 STEMI patients

Checked against the paper Randomized trialPublished by PepVault

The takeaway

Clear heart benefits in mice did not turn into an overall benefit in heart attack patients, and the early-dosing signal still needs further randomized trials.

Kind
Randomized trial
Studied in
People
Number studied
96
Published
2025
Journal
Cardiovasc Res

What they tested

The team tested whether recombinant human thymosin beta-4 (rhTB4) protects heart function after a blocked heart artery is reopened, in mice and in people with a major heart attack.

How the study was done

The team treated mice with heart injury, tested heart muscle cells in the lab, and ran a randomized, placebo-controlled, double-blind trial in 96 patients with STEMI (a major type of heart attack) after PCI (a procedure that reopens the blocked artery). Patients were followed for 90 days.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking Thymosin Beta-4? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

In mice with I/R (heart injury where blood flow is cut off and then restored), 7 days of rhTB4 prevented heart dysfunction and fibrosis (scarring) at 28 days and lowered plasma NT-proBNP, a heart-related blood marker, at 1 and 28 days. Blocking ErbB2 removed these benefits on heart function and remodeling in the I/R mice. In a second mouse model with a permanently tied-off artery, rhTB4 improved heart function and shrank infarct size at 8 weeks. In the trial, infarct area did not differ significantly between the rhTB4 and placebo groups overall, but the 43 patients who got their first dose within 8 h after PCI had smaller infarct areas than placebo at 90 days.

What it doesn’t show

The human trial missed its overall comparison, and the positive result comes from a subgroup defined by dosing time. The heart function, scarring and cell results come from mice and lab-grown cells, not people.

The paper

Zhang et al. Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion. Cardiovasc Res. 2025.

The compounds

More studies on Thymosin Beta-4

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking Thymosin Beta-4? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo